drugset / Trial / NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib or venetoclax.
Timeline
- Start
- 2023-09-12
- Primary completion
- 2025-06-12
- Completion
- 2026-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRT2527 | Unknown | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |